TABLE 3

Mean changes from baseline by treatment group

PlaceboMetforminLifestyleP*
n108210731079
Weight (kg)
    At 6 months−0.32 ± 0.14 (−0.3)−2.26 ± 0.14 (−2.4)−6.73 ± 0.14 (−7.2)<0.001
    At year 1−0.42 ± 0.17 (−0.4)−2.72 ± 0.17 (−2.9)−6.76 ± 0.17 (−7.2)<0.001
BMI (kg/m2)
    At 6 months−0.12 ± 0.05 (−0.4)−0.81 ± 0.05 (−2.4)−2.41 ± 0.05 (−7.1)<0.001
    At year 1−0.15 ± 0.06 (−0.4)−0.97 ± 0.06 (−2.9)−2.42 ± 0.06 (−7.1)<0.001
Fasting glucose (mg/dl)
    At 6 months0.20 ± 0.30 (0.2)−3.99 ± 0.30 (−3.7)−4.66 ± 0.30 (−4.4)<0.001
    At year 10.63 ± 0.36 (0.6)−4.18 ± 0.36 (−3.9)−4.94 ± 0.36 (−4.6)<0.001
HOMA-IR at year 10.36 ± 0.13 (5.1)−1.10 ± 0.13 (−15.3)−1.59 ± 0.12 (−22.7)<0.001
Waist (cm) at year 1−0.69 ± 0.19 (−0.7)−2.23 ± 0.19 (−2.1)−6.36 ± 0.19 (−6.1)<0.001
Waist-to-hip ratio at year 1−0.002 ± 0.001 (−0.2)−0.008 ± 0.001 (−0.9)−0.021 ± 0.001 (−2.3)<0.001
Activity at year 1 (MET h/week)1.39 ± 0.72 (8.2)1.65 ± 0.72 (10.0)6.60 ± 0.72 (42.6)<0.001
  • Data are means ±SE (% of baseline); % baseline is derived by dividing the mean at baseline with the mean change.

  • *

    * Pvalue represents the mean difference in characteristics among the three treatment groups using ANOVA.